Roche getting under the skin of biosimilar competition
Subcutaneous versions of its biologic blockbusters - including Mabthera and Herceptin - will help protect against biosimilar competition, says Roche.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs